Search

everythinglearnresearchcommunity

for

Search:↓

The document concludes that better tools are needed to measure skin disease severity in dermatomyositis and cutaneous lupus erythematosus, and introduces the DSSI and CLASI as reliable instruments.

The document concludes that recognizing and treating cutaneous lupus erythematosus early is crucial for managing the skin and potential systemic symptoms.

Excluding alopecia and mucous membrane components from the CLASI-A score reduces its effectiveness in capturing important disease activity.

The CLASI is a reliable tool for measuring the severity of cutaneous lupus erythematosus.

The European Society of Cutaneous Lupus Erythematosus created a questionnaire to standardize patient assessment and improve care for cutaneous lupus.

Most people with systemic lupus erythematosus have skin problems, and skin symptoms are often the first sign of the disease.

Immunosuppressive and anti-TNF therapies in IBD patients can increase the risk of skin cancer and cause various skin issues.

Lupus affects the body and skin, causing joint pain and skin issues that can be treated with steroids and antimalarial drugs.

Therapeutic intervention improved the quality of life for Japanese lupus patients with skin issues.

Skin problems are common in Lupus patients and can indicate the disease's severity, requiring specific treatments and lifestyle changes.

Hydroxychloroquine may help delay skin damage in lupus patients.

The conclusion is that early diagnosis of skin signs linked to diseases like Lupus, Dermatomyositis, and Rheumatoid Arthritis is crucial to prevent serious complications.

Higher EULAR/ACR scores in SLE patients predict more organ damage.

Apremilast shows promise for several skin conditions but needs more research.

Treating skin conditions with both psychological and dermatological care improves patient outcomes and can save costs.

Some growth factors, while important for normal body functions, can cause diseases when not regulated properly.

Men are more likely to get infectious skin diseases, while women are more prone to autoimmune and pigment-related skin conditions, influenced by biological and environmental factors.

Understanding how Regulatory T Cells work could help create treatments for certain skin diseases and cancers.

Alopecia Areata has no guaranteed treatment for hair regrowth, but options like corticosteroids and minoxidil are used, with future research focusing on genetic and immune therapies.

Skin diseases are common and can significantly affect people's lives; better outcome measures and ethical clinical trials are needed to improve dermatology care.

Hidradenitis suppurativa is a chronic skin condition more common in women, linked to genetics and lifestyle factors, and associated with various other health issues.

Tofacitinib is a promising treatment for children with rheumatic diseases.

Cannabinoids may help some skin conditions but more research is needed.

Certain gene variations and different levels of BDNF and CRH hormones are linked to vitiligo.

The CLASI is useful but needs revision to accurately assess all cutaneous lupus erythematosus subtypes.

Early treatment of Lupus Erythematosus Alopecia can prevent permanent hair loss, and various medications are effective.

Many patients with cutaneous lupus erythematosus experience hair loss and nail problems, which are important for diagnosis and treatment.

The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.

Lupus is a complex disease that requires personalized treatment because it varies greatly between individuals.

Non-scarring hair loss in lupus patients often responds well to treatment and doesn't lead to scarring.